Menu

Not sure where to start?

Take the quiz

 Explore All Protocols Membership
Explore
How It Works The Science Blog FAQs About Contact
Weight Loss

Ready to lose weight?

Start here
Explore
The Shed ProtocolYour weight loss, reimagined. The Burn ProtocolIgnite your metabolism. Weight Loss Overview BMI Calculator FAQs
Energy & Drive

Tired, sluggish, not yourself?

Take the assessment
Explore
The Apex ProtocolPeak performance, naturally. The Drive ProtocolFuel the fire that makes you, you. Hormone Health Overview Hormone Assessment The Science
Sexual Wellness

Restore your confidence

Get started
Explore
The Desire ProtocolConfidence when it counts. Membership FAQs
Anti-Aging & Longevity

Invest in your future self

Find your protocol
Explore
The Rewind ProtocolTurn back the clock. The Ignite ProtocolFuel every cell. Peptides Overview Peptide Calculator The Science
Hair & Skin

Clinically-proven regrowth

Start your protocol
Explore
The Crown ProtocolYour crown, restored. The Glow ProtocolReveal your best skin. FAQs
Sleep & Recovery

Better rest starts here

Find what works
Explore
The Drift ProtocolRest that restores. The Reclaim ProtocolTake back control. FAQs
All Protocols  ›  Anti-Aging  ›  The REWIND Protocol
The REWIND Protocol vial
Longevity · Growth Hormone

The REWIND Protocol

Sermorelin · GHRH
  • Signals your pituitary gland naturally
  • Nightly SubQ injection before bed
  • Refrigerated, shipped from licensed pharmacy

Nightly injection, subQ · Refrigerated shipment

Choose your starting dose
100 mcg
$129/mo
200 mcg
$159/mo
300 mcg
$189/mo
$129 / month
First month Just $— · then —/mo
Prescription only Free shipping Provider review in 24h US-licensed pharmacy

Nightly sublingual sermorelin troche — dissolves under the tongue before bed. Same growth-hormone signaling pattern, no needles. Bioavailability is lower than injection; your provider dose-adjusts accordingly.

Nightly, sublingual · Room-temperature shipment

Choose your starting dose
200 mcg
Starter dose
400 mcg
Standard
$379 / month
Prescription only Free shipping Provider review in 24h US-licensed pharmacy
What It Is

Support your body's growth hormone release — the clean peptide.

  • Tells your body to release more growth hormone
  • Supports deeper sleep and faster recovery
  • Helps with skin elasticity and collagen
  • Works with your body's natural signals
Featured Image images/rewind-science.png
The REWIND Protocol
How it works

How Rewind actually works.

Rewind is a peptide that asks your pituitary to release more of its own growth hormone — naturally, in the rhythm your body already uses. No synthetic hormone, no overriding your system.

Most patients notice changes in sleep quality, recovery, and body composition over three to six months. Your provider tracks markers and adjusts the protocol as you progress.

Rewind Protocol · Sermorelin
Board-certified physicianslicensed in your state
Compounded by a US pharmacylicensed, audited, traceable
Free, discreet shippingincluded in your subscription
What You’ll Take

One injection before bed.

Sermorelin — a GHRH analog that works with your body's natural pulsatile rhythm. Inject subcutaneously before sleep.

Why This Protocol

The anti-aging peptide your body recognizes.

Sermorelin works with your pituitary gland, not against it. A natural signal, amplified.

About this protocol

Technical and clinical context our providers use when evaluating intake for GHRH-analog therapy.

The REWIND Protocol clinical context
What is sermorelin?
  • Your body releases its own growth hormone — instead of being injected with it (GHRH analog that signals the pituitary)
  • Times with your natural rhythm — nightly injection before bed, so the pulse hits when sleep would
  • One subcutaneous shot per night
  • Provider intake first. Follow-up review based on how you respond.
  • For adults focused on recovery, sleep depth, and body-composition support — historically FDA-approved as Geref (discontinued in 2008 for commercial reasons, not safety)
The REWIND Protocol — Sermorelin
Storage & handling
  • Refrigerate at 36–46°F (2–8°C) before reconstitution.
  • After reconstitution with bacteriostatic water, refrigerate and use within 14–28 days.
  • Discard if cloudy, discolored, or contains particulates.
  • Each shipment includes alcohol pads, syringes, bacteriostatic water, and a sharps container.
  • Compounded under USP <797> sterile guidelines in a licensed US pharmacy.

Your Recovery Arc

Week 1-2

Nightly injections begin. Sleep quality may improve first.

Month 1

Recovery time between workouts shortens. Energy feels different.

Month 3

Skin elasticity, body composition, and overall vitality improving.

Month 6+

Sustained anti-aging benefits. Provider monitors and adjusts.

Your timeline to treatment

From personalized intake to ongoing support, we help you get — and stay — on track.

Start The REWIND Protocol in 5 simple steps

Answer a few questions about your health, goals, and history — all online, no in-person appointment needed. You'll find out if you're eligible within 24 hours.

Take your online intake on your phone

A US-licensed clinician reviews your intake, follows up on anything that needs clarification, and signs your prescription — typically within 24 hours.

A licensed clinician reviews your intake

Your Rx is compounded in a US-licensed 503A pharmacy under USP <797> sterile standards, lab-tested, sealed, and shipped — never sitting on a shelf.

US-licensed 503A pharmacy compounds your Rx

Your shipment lands at your door — refrigerated where required, with everything you need to start: vials, alcohol pads, syringes, and step-by-step guidance.

Your shipment arrives at your door

Ongoing care from our medical team — quick re-checks, dose adjustments when needed, and 24/7 access to your provider whenever a question comes up.

Ongoing care from your provider

Peer-reviewed research and regulatory documents our medical team consults when evaluating intake for this protocol.

U.S. Food and Drug Administration (Federal Register)

Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

FDA confirmed the branded sermorelin product GEREF (originally approved under NDA 19-863 in 1990 and NDA 20-443 in 1997) was discontinued in 2008 for business reasons and not for any safety or effectiveness concern.
U.S. Food and Drug Administration — Federal Register, Vol. 78, No. 42, pp. 14095-14096 (Document 2013-04827) 2013

View source

U.S. Government Publishing Office (GovInfo)

Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness - GovInfo Granule Metadata

Official government archive metadata mirror confirming the FDA Federal Register notice on GEREF (sermorelin acetate) historical NDA approvals and non-safety withdrawal.
U.S. Food and Drug Administration — Federal Register, 78 FR 14095 2013

View source

Journal of Clinical Endocrinology & Metabolism (Oxford Academic)

Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy

Multicenter trial in 110 prepubertal GH-deficient children showed that daily subcutaneous sermorelin (30 mcg/kg) at bedtime increased mean height velocity from 4.1 to 8.0 cm/yr at 6 months, with good tolerability.
Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S (Geref International Study Group) — Journal of Clinical Endocrinology & Metabolism, Volume 81, Issue 3, Pages 1189-1196 1996

View source

BioDrugs (Springer)

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency

Comprehensive review of sermorelin pharmacology, diagnostic use, and pediatric efficacy data, with safety profile noting transient facial flushing and injection-site pain as the most common adverse events.
Prakash A, Goa KL — BioDrugs, Volume 12, Issue 2, Pages 139-157 1999

View source

Molecular Endocrinology (Oxford Academic)

Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone

Foundational paper that cloned and characterized the pituitary-specific GHRH receptor, establishing the G-protein coupled receptor mechanism by which sermorelin and other GHRH analogs stimulate endogenous growth hormone release.
Mayo KE — Molecular Endocrinology, Volume 6, Issue 10, Pages 1734-1744 1992

View source

Reviews in Endocrine and Metabolic Disorders (Springer)

Growth hormone-releasing hormone receptor (GHRH-R) and its signaling

Modern peer-reviewed review of GHRH receptor structure, signaling, splice variants, and therapeutic relevance of GHRH agonists like sermorelin across multiple disease contexts.
Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV — Reviews in Endocrine and Metabolic Disorders, Volume 26, Issue 3, Pages 343-352 2025

View source

Journal of Clinical Endocrinology & Metabolism (Oxford Academic)

Evidence for a limited growth hormone (GH)-releasing hormone (GHRH)-releasable quantity of GH: effects of 6-hour infusions of GHRH on GH secretion in normal man

Early adult human GHRH infusion study demonstrating that GHRH stimulates pulsatile GH release from the pituitary, with the magnitude of release limited by available pituitary GH stores.
Vance ML, Kaiser DL, Evans WS, Thorner MO, Furlanetto R, Rivier J, Vale W, Perisutti G, Frohman LA — Journal of Clinical Endocrinology & Metabolism, Volume 60, Issue 2, Pages 370-375 1985

View source

Journal of Clinical Endocrinology & Metabolism (Oxford Academic)

Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy

Demonstrated that continuous 14-day GHRH administration in adults did not desensitize or deplete pituitary somatotrophs, supporting chronic GHRH-based therapy as a viable approach.
Vance ML, Kaiser DL, Martha PM Jr, Furlanetto R, Rivier J, Vale W, Thorner MO — Journal of Clinical Endocrinology & Metabolism, Volume 68, Issue 1, Pages 22-28 1989

View source

Journal of Clinical Endocrinology & Metabolism (Oxford Academic)

Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline

Endocrine Society clinical practice guideline covering diagnosis, treatment, and safety considerations for adult growth hormone deficiency, including GHRH-arginine testing methodology.
Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML — Journal of Clinical Endocrinology & Metabolism, Volume 96, Issue 6, Pages 1587-1609 2011

View source

Clinical Interventions in Aging (Dove Medical Press / PubMed Central)

Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

Editorial discussing sermorelin as a physiologically gentler alternative to recombinant GH for age-related GH insufficiency, citing preserved negative feedback, episodic release, and lower risk of supraphysiologic IGF-1 levels.
Walker RF — Clinical Interventions in Aging, Volume 1, Issue 4, Pages 307-308 2006

View source

United States Pharmacopeia (USP)

USP General Chapter <797> Pharmaceutical Compounding - Sterile Preparations

The official USP standard governing sterile compounding (including injectable peptides like sermorelin) covering facility design, environmental monitoring, beyond-use dating, personnel training, and the new Category 1/2/3 CSP framework. Compounding pharmacies preparing sermorelin must comply with this chapter.
United States Pharmacopeial Convention — USP-NF 2023 Issue 1 (Official November 1, 2023) 2023

View source

U.S. Food and Drug Administration

Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act

Official FDA page describing the legal framework under which 503A pharmacies may compound from bulk drug substances. Sermorelin is permitted for 503A compounding via the 'component of a previously FDA-approved drug' pathway (former NDA 19-863 / 20-443, GEREF), since the original branded product was not withdrawn for safety or effectiveness.
U.S. Food and Drug Administration — FDA.gov Human Drug Compounding Program 2025

View source

U.S. Food and Drug Administration (Federal Register / FDA Guidance)

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability

Finalized January 2025 FDA guidance defining the interim regulatory policy for 503A pharmacies compounding from bulk drug substances; relevant to the current legal pathway for compounded sermorelin in the United States.
U.S. Food and Drug Administration — Federal Register, January 7, 2025 2025

View source

Note on Regulatory Status (Editorial Disclosure)

Sermorelin Regulatory Status Disclosure

TRANSPARENCY NOTE: Branded sermorelin (GEREF) historically held FDA approval for pediatric GH-deficiency diagnosis and treatment but was discontinued by the manufacturer in 2008 (not for safety or efficacy reasons). Sermorelin is NOT currently FDA-approved for any indication in adults. It remains legally available in the U.S. only via 503A compounding pharmacies under valid prescription. This disclosure must accompany consumer-facing references for Nuvari's REWIND Protocol.
2026

View source
Medical notice. Sermorelin is not currently FDA-approved for any indication; it is legally available only through 503A compounding pharmacies after a licensed physician's prescription. The REWIND Protocol is not appropriate for active malignancy, untreated obstructive sleep apnea, or known hypersensitivity to sermorelin. No long-term (>1 year) randomized safety data exist in healthy adults using compounded sermorelin for wellness indications — discuss with your physician. Statements on this site have not been evaluated by the FDA.
Pairs With

What Rewind stacks with.

The protocols our providers most often add alongside this one.

Enclomiphene · Hormone Optimization

Apex

Peak performance, naturally.
→
Cellular Energy · NAD+

Ignite

Relight your cells. Reclaim your energy.
→
Skin · Dermatology

Glow

Prescription skin, simplified.
→